AZN INVESTOR DEADLINE: AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitPRNewsWire • 01/13/25
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancerBusiness Wire • 01/13/25
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung CancerBusiness Wire • 01/13/25
Levi & Korsinsky Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 AZNAccesswire • 01/13/25
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZNGlobeNewsWire • 01/13/25
AZN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewsWire • 01/11/25
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZNAccesswire • 01/10/25
Investors who Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky About Pending Class Action - AZNAccesswire • 01/10/25
Class Action Filed Against AstraZeneca PLC (AZN) Seeking Recovery for Investors – Contact Levi & KorsinskyAccesswire • 01/10/25
AstraZeneca PLC Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Shareholders of the Class Action Against AZNAccesswire • 01/09/25
February 21, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AZNAccesswire • 01/09/25
ASTRAZENECA SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AstraZeneca PLC - AZNGlobeNewsWire • 01/09/25
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZNAccesswire • 01/09/25
AZN Investors Have Opportunity to Lead AstraZeneca PLC Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!Accesswire • 01/08/25
BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's LymphomaAccesswire • 01/08/25
ASTRAZENECA SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AstraZeneca PLC - AZNGlobeNewsWire • 01/08/25
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZNAccesswire • 01/07/25
Deadline Approaching: AstraZeneca PLC (AZN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. SmithBusiness Wire • 01/07/25
Investors Are Invited To Join The Schall Law Firm In A Securities Fraud Case Against AstraZeneca PLCAccesswire • 01/07/25
Asher Bio Announces Clinical Supply Agreement to Enable Evaluation of Etakafusp Alfa (AB248) in Combination with Rilvegostomig in a Global Phase 1b/2 Study in Non-Small Cell Lung Cancer (NSCLC)Business Wire • 01/07/25
AZN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitBusiness Wire • 01/07/25